Jeffrey Tosoian, MD, MPH, recaps recent updates from the TheraP, ARAMIS, TITAN, ARASENS, and ATLAS prostate cancer trials.
In this video, Jeffrey Tosoian, MD, MPH, recaps noteworthy prostate cancer abstracts presented at the 2022 American Society of Clinical Oncology Annual Meeting. Tosoian is an assistant professor in the Department of Urology, Division of Urologic Oncology, at Vanderbilt University Medical Center.
The following 5 abstracts are summarized:
Abstract 5000 (Hofman et al): TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603)
Abstract 5044 (Morgans et al): Progression patterns by types of metastatic spread, prostate-specific antigen (PSA), and clinical symptoms: Post-hoc analyses of ARAMIS
Abstract 5066 (Agarwal et al): Genomic aberrations associated with overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or placebo (PBO) plus androgen deprivation therapy (ADT) in TITAN
Abstract 5078 (Saad et al): Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial
Abstract 5084 (Sandler et al): Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC)